The synthesis and anti-proliferative effects of β-elemene derivatives with mTOR inhibition activity

被引:67
作者
Xu, Liying
Tao, Shujuan
Wang, Xianming
Yu, Zhiying
Wang, Minwei
Chen, Duo
Jing, Yongkui [1 ]
Dong, Jinhua
机构
[1] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China
[3] Mt Sinai Sch Med, New York, NY 10029 USA
基金
中国国家自然科学基金;
关键词
beta-elemene derivatives; synthesis; anti-proliferation; mTOR;
D O I
10.1016/j.bmc.2006.03.041
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fourteen beta-elemene derivatives containing a piperazine, a morpholine, a tetrahydropyrrole, a thiophenylethylamine, or a cyclohexamine group were synthesized. The structures of these beta-elemene derivatives were characterized with IR, H-1 NMR, MS, and elemental analyses. All these derivatives had an increased anti-proliferative activity in human cervix epitheloid carcinoma HeLa, gastric carcinoma SGC-7901, and leukemia K562 cells comparing with that of beta-elemene. Among these derivatives, 13,14-bis(cis-3,5-dimethyl-1-piperazinyl)-beta-elemene (IIi), 13 14-bis[2-(2-thiophenyl)ethylamino]-beta-elemene (IIm), and 13,14-bis(cyclohexamino)-beta-elemene (IIn) were the most potent agents. IIi, IIm, and IIn inhibited K562 cell growth with an IG(50) below 5 mu M that was correlated with mTOR activity inhibition. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5351 / 5356
页数:6
相关论文
共 13 条
[1]  
Aapro M, 1998, SEMIN ONCOL, V25, P7
[2]   Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system [J].
Dai, J ;
Weinberg, RS ;
Waxman, S ;
Jing, YK .
BLOOD, 1999, 93 (01) :268-277
[3]  
GAO YT, 1983, B CHIN MAT MED, V8, P31
[4]   Dysregulation of the TSC-mTOR pathway in human disease [J].
Inoki, K ;
Corradetti, MN ;
Guan, KL .
NATURE GENETICS, 2005, 37 (01) :19-24
[5]  
Jia W.M., 1991, CHIN J ORG CHEM, V11, P608
[6]   Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience [J].
Kollmannsberger, C ;
Mross, K ;
Jakob, A ;
Kanz, L ;
Bokemeyer, C .
ONCOLOGY, 1999, 56 (01) :1-12
[7]  
Manegold C, 1999, SEMIN ONCOL, V26, P23
[8]   PI3K/Akt/mTOR pathway as a target for cancer therapy [J].
Morgensztern, D ;
McLeod, HL .
ANTI-CANCER DRUGS, 2005, 16 (08) :797-803
[9]   Impact of the composition of combustion generated fine particles on epithelial cell toxicity: influences of metals on metabolism [J].
Okeson, CD ;
Riley, MR ;
Fernandez, A ;
Wendt, JOL .
CHEMOSPHERE, 2003, 51 (10) :1121-1128
[10]  
QIAN J, 1996, CHIN J CLIN ONCOL, V23, P453